
Many investors are looking for assets that don’t move with stocks are inflation proof. Are REITs the answer?

Many investors are looking for assets that don’t move with stocks are inflation proof. Are REITs the answer?

The economics of direct care are straightforward. Here are the three variables to track.


Fear that a market-punishing recession is right around the corner seems ubiquitous.

American Hospital Association requesting a task force from the justice department to investigate commercial health insurance companies in the Medicare Advantage program

What can be done about it?

Eli Lilly and Company’s Mounjaro received FDA approval for its type 2 diabetes drug

Employers and insurers are paying far more in hospital costs than they would if they paid at rates comparable to Medicare, a new RAND report found.

Overall health spending grows more slowly than GDP

Lower household income and requiring multiple medications play large roles

Latest numbers show prices rose at a slightly slower pace in April.

Rising expenses, lower volume, and lower revenue drive profit margins lower

The Federal Reserve raised short-term interest rates 0.5%

Study shows evidence that volume and revenue may be rebounding

Is the economy on the verge of a crash? Let’s examine what the facts say.

Office of the Inspector General found that some Medicare Advantage organizations were delaying or denying care that should have been allowed.

Contrary to popular belief, high volatility is not a terroristic threat to investors. Rather, it is a natural part of the stock market.

Study shows most consumers dissatisfied with the cost of care

COVID-19 vaccines and therapies were the main drivers

Pandemic greatly accelerated consolidation, threatening the independent practice of medicine

New York becomes 25th state to grant nurse practitioners full practice authority

Nonprofit hospitals are supposed to give back to the community to justify their tax breaks

Only 12 transactions were announced in Q1, the lowest recorded since tracking began in 2016

Patients want controls on drug prices and more oversight on the industry

Patients often don’t know where to find information on their benefits or don’t have time to do so